Oracin

Drug Profile

Oracin

Alternative Names: Oracine; VUFB 16956

Latest Information Update: 14 Apr 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator VUFB
  • Developer Synthesia; Zentiva
  • Class Antineoplastics; Ethanolamines; Isoquinolines; Small molecules
  • Mechanism of Action DNA inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 15 Sep 2003 Leciva has merged with Slovakofarma to form Zentiva
  • 14 Feb 2002 Profile reviewed and compound appears to be in active development
  • 15 Feb 2001 Phase-II clinical trials for Cancer in Czech Republic (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top